Re-assessment of methylphenidate-based proprietary products in attention-deficit hyperactivity disorder in response to a request from the Directorate-General for Health and renewal of inclusion.
-
Clinical Benefit
Substantial
The actual benefit of RITALIN and RITALIN LP is substantial in the context of the comprehensive therapeutic management of ADHD in children aged 6 years and over when psychological, educational and social management alone proves insufficient.
The actual benefit of RITALIN, tablet, is still substantial in treating narcolepsy with or without cataplexy where modafinil is ineffective in adults and children aged over 6 years.
Listen
